Sept. 18 Financial Quick Takes: IGM gains in first trading day; plus a follow-on roundup, BenevolentAI, UCSF’s InVent Fund and Versantis

First-day pop for IGM on NASDAQ
Oncology antibody company IGM Biosciences Inc. (NASDAQ:IGMS) gained $8.30 (52%) to $24.30 in its first day of trading after raising $175 million in its IPO. IGM sold 10.9 million shares at $16, the midpoint of its proposed range; it had boosted the number

Read the full 483 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE